Artivion Inc (AORT)vsBoston Scientific Corp (BSX)
AORT
Artivion Inc
$20.12
-3.45%
HEALTHCARE · Cap: $971.11M
BSX
Boston Scientific Corp
$48.55
+0.76%
HEALTHCARE · Cap: $69.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 4394% more annual revenue ($20.61B vs $458.69M). BSX leads profitability with a 17.3% profit margin vs 2.5%. BSX appears more attractively valued with a PEG of 0.57. BSX earns a higher WallStSmart Score of 76/100 (B+).
AORT
Hold41
out of 100
Grade: D
BSX
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-31.9%
Fair Value
$30.41
Current Price
$20.12
$10.29 premium
Margin of Safety
-25.6%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
17.5% revenue growth
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
2.5% margin — thin
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book, Revenue Growth. Revenue growth of 17.5% demonstrates continued momentum.
Bull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 80.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Key Dynamics to Monitor
AORT profiles as a growth stock while BSX is a mature play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.26 — expect wider price swings.
AORT is growing revenue faster at 17.5% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 41/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?